Products and services

Contact and locations

Activery The amorphization specialist

Activery The amorphization specialist

Activery believes that amorphous drugs provide new and innovative routes to final dosage forms with differentiated pharmacokinetics

Service analyse DSC

SERVICE ANALYSE DSC ET TGA Activery offre aussi le service d analyse thermique (analyse DSC et TGA) en externalisation. Nous effectuons l analyse thermique pour différents produits chimies, polymères, cosmétiques et , spécialement, pour produits pharmaceutiques come des principes actives ou for...

Creating new paths to differentiated medicines

Creating new paths to differentiated medicines

In Activery we believe that solid state modifications may lead to a critical changes in your active pharmaceutical, thus to a differentiated drug or to a brand new innovative medicine  

Activery, the solid state specialist

Activery, the solid state specialist

Activery possess unrivalled specialist expertise about different crystallization techniques and expert knowledge in the field of solid state modulation.  

Particles and nanoparticles for special uses

Particles and nanoparticles for special uses

In Activery, we design and produce particles for special uses where size matters such as nanoparticles for cancer treatment. Through our technology you would enable new administration routes or renewed performance of your drug formulation.  

Amorphous drugs
Molecular and Thermodynamic Aspects of Solubility Advantage from Solid Dispersions PDF Print E-mail
Molecular and Thermodynamic Aspects of Solubility Advantage from Solid Dispersions
AbstractFull Text HTMLHi-Res PDF[186 KB]Shyam Sunder Bansal†, Aditya Mohan Kaushal‡ and Arvind Kumar Bansal*‡
Department of Pharmaceutics and Department of Pharmaceutical Technology (Formulations), National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar, Punjab 160 062, India
Mol. Pharmaceutics, 2007, 4 (5), pp 794-802
DOI: 10.1021/mp7000796
Publication Date (Web): September 15, 2007
Copyright © 2007 American Chemical Society
† Department of Pharmaceutics.
, ‡ Department of Pharmaceutical Technology (Formulations).
, * To whom correspondence should be addressed. Mailing address: Department of Pharmaceutical Technology (Formulations), National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S.A.S. Nagar (Mohali), Punjab 160 062, India. Phone: +91-172-2214682-87 . Fax: +91-172-2214692. E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it , This e-mail address is being protected from spambots. You need JavaScript enabled to view it .
Abstract
The solubility behavior of solid dispersions of two drugs with similar structures was studied. Valdecoxib (VLB) and etoricoxib (ETB) were used as model drugs, and their solid dispersions were prepared with 1, 2, 5, 10, 15, and 20% w/w poly(vinylpyrrolidone) (PVP) by the quench cooling method. The interactions between the drug and polymer molecules were studied by Fourier transform infrared spectroscopy (FT-IR). The thermodynamic aspects of solubility behavior were studied by plotting vant Hoff plots. Both the drugs showed significant differences in their solubility behavior. In the case of VLB, solubility was found to increase significantly with increasing PVP concentration. ETB however did not show any significant solubility enhancement and was found to have decreased solubility at high PVP concentrations. H-bonding interactions were established between VLB and PVP molecules, while none were observed in ETB-PVP dispersions. Solution thermodynamics of amorphous and crystalline forms of both the drugs were studied by vant Hoff plots. The results obtained showed very high negative value of Gibbs free energy for VLB as compared to ETB, thus demonstrating high spontaneity of VLB solubilization. Entropy of amorphous VLB was found to be highly favorable, while being slightly unfavorable for ETB. From this study H-bonding interactions were found to play a major role in dictating the solubility behavior of these drugs from solid disperions.

 
 
Drugs with annual sales totalling over US$86 B in 2007 are due to go off patent by 2012. PDF Print E-mail

Looming patent expiry a major force in driving valuation


Drugs with annual sales totalling over US$86 B in 2007 are due to go off patent by 2012. Therefore, the application of novel drug delivery technologies to such existing therapeutics is an attractive means of prolonging the commercial viability of marketed drugs.

Technologies are more difficult to value than products in clinical development because the technical risks or success rates are less well documented, and costs and timescales are less predictable.

It is very important to benchmark when valuing technologies and to have a thorough understanding of the risks and rewards.

This new report covers the range of strategies and offerings available to the deal maker, and is vital for understanding growth and survival in volatile markets.

Title Index:

1. Introduction

2.Market Overview
2.1 Types of Drug Delivery
2.2 Development of the Drug Delivery Market
2.3 The Current and Evolving Market
2.4 Future Market Challenges
2.5 Drug Delivery Companies
2.5.1 Principal Players in Drug Delivery
2.5.2 The Changing Landscape: M&A Activity
2.5.3 The True Scope of the Drug Delivery Sector

3.Key Drivers in Drug Delivery
3.1 Improving the Therapeutic Index
3.2 Patient Compliance
3.3 Patent Prolongation
3.4 Life Cycle Management

4. Commercialisation Strategies
4.1 Introduction
4.2 Returns to Innovation
4.3 Drug Delivery Product Offerings
4.4 Exploitation Strategies
4.5 Business Models
4.6 Product, Strategy and Business Models for Drug Delivery Technology
4.7 Applicability to Segments of the Pharmaceutical Product Life Cycle
4.8 Assessment of Attractiveness of Each Option
4.8.1 Divestment to a Service-Based Company
4.8.2 Licensing to Pharmaceutical Companies
4.8.3 Sales of Devices
4.8.4 Service Offering
4.8.5 Development of Drugs in Collaboration with other Companies
4.8.6 In-House Drug Development
4.9 Compatibility of Product Offerings
4.10 Conclusion

5. Alliances in Drug Delivery
5.1 Drug Delivery Deals Database
5.2 Drug Delivery Deal Activity
5.3 Financial Analysis of Drug Delivery Deals

6. Major Pharmaceutical Company Drug Delivery Deal Activity
6.1 Johnson & Johnson
6.2 Pfizer
6.3 GlaxoSmithKline (GSK)
6.4 Novartis
6.5 Sanofi -aventis
6.6 Roche
6.7 AstraZeneca
6.8 Merck & Co
6.9 Abbott Laboratories
6.10 Wyeth

7. Valuation Methods
7.1 Integrated Benchmarking and ENPV Calculation
7.2 Other Methods
7.3 Benchmarking
7.3.1 Feasibility Search
7.3.2 Information Gathering and Analysis
7.3.3 Approximate Valuation
7.3.4 Refi nement of Valuation
7.4 Expected Net Present Value
7.5 Agreement Structure
7.5.1 Value Sharing
7.5.2 Risk Sharing
7.6 Valuation of Drug Delivery Systems
7.6.1 Enabling Technology
7.6.2 Enhancing Technology

8. Drug Delivery Alliance Development Process
8.1 Needs Identifi cation
8.1.1 Driving Factors
8.1.1.1 Market Drivers
8.1.1.2 Technology Drivers
8.1.2 Tools Needs Identifi cation
8.1.2.1 Portfolio Analysis
8.1.2.2 Value Chain Analysis
8.2 Identifying Opportunities and Partners
8.3 Development of Commercial Relationships